Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
113 Cards in this Set
- Front
- Back
Cytokine Rx: RCC, Metastatic Melanoma
|
Aldesleukin (IL2)
|
|
Cytokine Rx: Anemias (esp in renal failure)
|
Erythropoietin (epoietin)
|
|
Cytokine Rx: Recovery of bone Marrow
|
Filgastrim (Granulocyte Colony Stimulating Factor)
Sargramostim (granulocyte-macrophage colony stimulating factor) |
|
Cytokine Rx: Hep B/C, Kaposi, Leukemia, Malignant Malanoma
|
a-interferon
|
|
Cytokine Rx: Multiple Sclerosis
|
b-interferon
|
|
Cytokine Rx: Chronic granulomatous disease
|
y-interferon
|
|
Cytokine Rx: Thrombocytopenia
|
oprelvekin (IL11)
|
|
Cytokine Rx: Thrombocytopenia
|
Thrombopoietin
|
|
-afil
|
erectile dysfunction
|
|
-ane
|
inhalation general anesthetis
|
|
-azepam
|
benzo
|
|
-azine
|
phenothiazine (neuroleptic, antiemetic)
|
|
-azole
|
antifungal
|
|
-barbital
|
barbiturate
|
|
-caine
|
local anesthetic
|
|
-cillin
|
penicillin
|
|
-cycline
|
antibiotic, protein synthesis inhibitor
|
|
-etine
|
SSRI
|
|
-ipramine
|
TCA
|
|
-navir
|
protease inhibitor
|
|
-olol
|
b-blocker
|
|
-operidol
|
butyrophenone (neuroleptic)
|
|
-oxin
|
cardiac glycoside (inotropic agent)
|
|
-phylline
|
methylxanthine
|
|
-pril
|
ACE inhibitor
|
|
-terol
|
b-agonist
|
|
-tidine
|
H2-antagonist
|
|
-triptan
|
5-HT(1A) agonists (migraine use)
|
|
-tryptiline
|
TCA
|
|
-tropin
|
pituitary hormone
|
|
-zosine
|
a1-antagonists
|
|
Resistance Mechanism for penicillins/cephs
|
b-lactamase cleavage, or mutation/alteration of PBP (MRSA and resistant S. pneumos)
|
|
Resistance Mechanism for Aminoglycosides
|
(A) Acetylation modification (or adenylation or phosphorylation)
|
|
Resistance Mechanism for Vancomycin
|
D-ala --> D-lac
|
|
Resistance Mechanism for Chloramphenicol
|
Acetylation modification
|
|
Resistance Mechanism for Mecrolides
|
(M) Methylation
|
|
Resistance Mechanism for Tetracyclins
|
(T) Transport out of the cell of decreased upTake
|
|
Resistance Mechanism for Sulfonamides
|
Altered Enzyme (bacterial dihydropteroate synthetase)
also: decreased uptake, or increased PABA synthesis |
|
Resistance Mechanism for Quinolones
|
Altered Gyrase (or reduced uptake)
|
|
Antimicrobial prophylaxis: Meningococcal infection
|
rifampin (or minocycline)
|
|
Antimicrobial prophylaxis: Gonorrhea
|
Ceftriaxone
|
|
Antimicrobial prophylaxis: syphilis
|
Benzathine Pen G, amoxicillin in delivery
|
|
Antimicrobial prophylaxis:History of recurrent UTIs
|
TMP-SMX
|
|
Pneumocystis jiroveci
|
TMP-SMX or aerosolized pentamidine if sulfa allergic
|
|
Antimicrobial prophylaxis: endocarditis with surgical and dental procedures
|
penicillins
|
|
Mechanism of action: Pens, aztreonam, cephs
|
block cell wall synth by inhibiting peptidoglycan cross-linking
|
|
Mechanism of action: bacitracin, vancomycin
|
Block peptidoglycan synth
|
|
Mechanism of action: polymyxins
|
disrupt cell membranes
|
|
Mechanism of action: sulfonamides, trimethoprim
|
block nucleoide synthesis
|
|
mechanism of action: Quinolones
|
blocks DNA topoisomerase II
|
|
mechanism of action: rifampin
|
blocks mRNA synthesis
|
|
mechanism of action: chloramphenicol, macrolides, clindamycin, streptogramins (-quinupristin and dalfopristin), linezolids
be specific for macrolides, chloramphenicol, and clindamycin |
Block protein synthesis at 50S
macrolides: block translocation chloramphenicol: peptidyltransferase inhibition clindamycin: peptide bond formation |
|
Mechanism of action: aminoglycosides and tetracyclins (specifics for each)
|
block protein synthesis at 30s
aminoglycosides: misreading and complex formation blockage tetracyclins: prevent attachment of aminoacyl-tRNA |
|
antacids, milk, iron-chelators
|
inhibit tetracyclines
|
|
First Gen Cephs
|
Cefadroxil
Cefazolin "CePHs" |
|
2nd Gen Cephs
|
PUMA (Cefp, Cefu, Cefm, Cefa)
Loracarbef Cefotetan Cefonicid (nine letters) Cefoxitin (nine letters |
|
3rd gen Cephs
|
TIDE (Ceft, Cefi, Cefd, Cefe)
Moxalactam Cefoparazone (ten letters) Ceotaxime (ten letters) |
|
pseudomonas cephs
|
ceftazidime (3rd gen)
Cefepime (4th gen) |
|
gonorrhea ceph
|
ceftriaxone
|
|
1st gen cephs used against
|
PEcK - Proteus, E. coli, Klebsiella
|
|
2nd Gen Cephs used against
|
HEN PEcKS
Haemophilus, Enterobacter, Neisseria, Proteus, E. coli, Klebsiella, Serratia |
|
Linozolid mechanism
|
50 S and inhibits initiation complex (ribosomes and initiator tRNA)
|
|
Aminoglycosides mechanism
|
30s and inhibits initiation complex and causes misreading (FA also says it blocks the A-site)
|
|
Chloramphenicol mechanism
|
50S and blocks peptidyle transferase
|
|
Erythro Mechanism
|
50s and translocation step
|
|
Clindamycin Mechanism
|
50s and blocks peptide bond formation (and FA also says translocation step)
|
|
Lincomycin mechanism
|
50s and translocation step
|
|
Tetracycline mechanism
|
30s and blocks A-site
|
|
MRSA treatment
|
vancomycin
|
|
VRE (vancamycin resistant) treatment
|
linezolid and streptogramins
|
|
quinupristin and dalfopristin (what drug category? used for what?)
|
streptogramins, used for Vancomycin resistant bugs
|
|
Amantadine pnemonics
|
A man to dine takes off his coat.
Amantadine blocks influenzA (A) rubellA, and causes problems with your cerebellA) |
|
Sulfadrugs
|
Celecoxib, furosemide, probenicid, thiazides, tmp-SMX, sulfasalazine, sulfonylureas
|
|
SE of HMGCoA reductase
|
rhabdomyolysis
|
|
SE niacin
|
flushing, decreased by aspirin
|
|
SE Bile Acid Resins
|
dec. absorption of FSVs, contraindicated in patients with gallstones (increased new bile synth)
|
|
SE fibrates
|
myositis, increased LFTs
|
|
SE cholesterol absorption blockers (ezetimibe)
|
LFT increase (rare)
|
|
Insulin SE/Tox
|
hypoglycemia, hypersensitivity rxns, hypokalemia
|
|
Sulfonylureas SE/Tox
|
disulfiram effect (first gen)
(2nd gen) hyoglycemia |
|
Biguanides SE/Tox
|
LACTIC ACIDOOSIS
|
|
Glitazone SE/Tox
|
HEPATOTOXICITY, Weight gain, edema, CV toxicity
|
|
What kind of drug is this: tolbutamide
|
(1st gen) sulfonylurea (close K channels, increase insulin secretion)
|
|
What kind of drug is this: chlorpropramide
|
(1st gen) sulfonylurea (close K channels, increase insulin secretion)
|
|
What kind of drug is this: Glyburide
|
(2nd gen) sulfonylurea (close K channels, increase insulin secretion)
|
|
What kind of drug is this: glimepiride
|
(2nd gen) sulfonylurea (close K channels, increase insulin secretion)
|
|
What kind of drug is this: glipizide
|
(2nd gen) sulfonylurea (close K channels, increase insulin secretion)
|
|
What kind of drug is this: metformin
|
biguanide
|
|
What kind of drug is this: pioglitazone
|
glitazone (binds PPAR-y, causes increased insulin sensitivity peripherally)
|
|
What kind of drug is this: rosiglitazone
|
glitazone (binds PPAR-y, causes increased insulin sensitivity peripherally)
|
|
What kind of drug is this: Miglitol
|
a-glucoside inhibitor
|
|
what kind of drug is this: acarbose
|
a-glucoside inhibitor
|
|
What kind of drug is this: repaglitinide
|
meglitinide (binds potassium channels, like sulfonylureas, and increases insulin secretion.
|
|
What kind of drug is this: nateglinide
|
meglitinide (binds potassium channels, like sulfonylureas, and increases insulin secretion.
|
|
What kind of drug is this: sitagliptin
|
DPP-4 inhibitor: inhibit DPP4 breakdown of GLP1s
|
|
What kind of drug is this: vildagliptin
|
DPP-4 inhibitor: inhibit DPP4 breakdown of GLP1s
|
|
What kind of drug is this: saxagliptin
|
DPP-4 inhibitor: inhibit DPP4 breakdown of GLP1s
|
|
What kind of drug is this: exanatide
|
GLP1: increased insulin secretion and decreases glucagon secretoin
|
|
What kind of drug is this: liraglutide
|
GLP1: increased insulin secretion and decreases glucagon secretoin
|
|
What kind of drug is this: diazoxide
|
anti-meglitinide/sulfonyureas (potentiates potassium channels in b-cells and decreases insulin secretion)
|
|
H. Pylori teatment
|
Triple therapy: Metronidazole, Amoxicillin (or Tetracyclin), Bismuth
(MAke Tummy Better) Quad therapy: PPI added to Triple Therapy (Please MAke Tummy Better) |
|
What kind of drug is this: prochlorpromazine
|
antiemetic that blocks D2 receptors in the area postrema
|
|
what kind of drug is this: metoclopramide
|
antiemetic that blocks D2 receptors in the area postrema
|
|
Target of methotrexate
|
Nucleoside synthesis
|
|
target of 5fu
|
nucleoside synthesis
|
|
target of 6mp
|
nucleoside synthesis
|
|
target of alkylating agents
|
DNA (cross linking)
|
|
target of cisplatin
|
DNA (cross linking)
|
|
target of Anthracyclines
|
DNA (intercalating agents)
|
|
target of etoposide
|
DNA (topoisomerase II inhibitor)
|
|
target of palitaxil
|
cell division: inhibits microtubule disassembly
|
|
target of vinca alkaloids
|
cell division: inhibits microtubule formation
|
|
difference between etanercept infliximab and adalimumab
|
etanercept is a decoy TNFa receptor
infliximab is a TNFa antibody adalimumab is an antibody against TNFa receptors |